Who is sponsoring NCT00978302?

NCT00978302 is sponsored by Renovo.

What condition does NCT00978302 study?

NCT00978302 studies Cicatrix, Wound Healing.

What drugs are being tested in NCT00978302?

Interventions: Avotermin, Avotermin, Avotermin, Avotermin, Avotermin, Avotermin, Placebo (vehicle).

What is the status of NCT00978302?

NCT00978302 is currently COMPLETED.

Last reviewed 2009-09-15 · How we verify

A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised, Parallel Group Study to Investigate the Clinical Safety, Toleration, Systemic Pharmacokinetics and Local Pharmacodynamics of Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects.

NCT00978302 Phase 1 COMPLETED

The purpose of this study is to determine the safety and local toleration and histological effects of various dose levels of avotermin (Juvista) injected intradermally in healthy male volunteers.

Details

Lead sponsor	Renovo
Phase	Phase 1
Status	COMPLETED
Enrolment	55
Start date	2001-05
Completion	2001-08

Conditions

Cicatrix
Wound Healing

Interventions

Avotermin
Avotermin
Avotermin
Avotermin
Avotermin
Avotermin
Placebo (vehicle)

Primary outcomes

To determine the safety and local toleration of various dose levels of avotermin (Juvista) injected intradermally into healthy male volunteers. — Days 0 and 1 and either 3 and 4 or 7 and 8 in addition to Day 10. A single post-trial follow-up was made between days 17-24.

Countries

United Kingdom